MedPath

To study markers of cancer and effects of various medicines, Mycophenolate Mofetil, Methotrexate and Pimecrolimus in patients with ulcers in mouth causing burning sensation with spicy food.

Phase 4
Completed
Conditions
Health Condition 1: null- Patients having oral Lichen planus lesions and without any severe debilitating medical illness
Registration Number
CTRI/2017/04/008344
Lead Sponsor
Maulana Azad Institute of Dental Science
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Completed
Sex
Not specified
Target Recruitment
60
Inclusion Criteria

1. Patients older than 8 years with histologically proven Lichen Planus cases, were included in the study.

Exclusion Criteria

1. Lichenoid contact reaction due to any medication, mouthrinse, toothpaste or any other agent.

2. Patients who had received any therapy for Lichen Planus within past 8 weeks.

3. Any malignant or viral involvement in mouth .

4. Pregnant or nursing women also excluded.

5. Patients not willing to participate in the study

6. Patients whose complete follow up is lacking

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
To compare therapeutic potential of <br/ ><br>Pimecrolimus, Mycophenolate mofetil and <br/ ><br>Methotrexate in oral lichen planus(OLP)using IL-6 as a marker of infllammatory <br/ ><br>Response and Cdk4 & p16 as markers of malignant potential. <br/ ><br>Timepoint: 3 months 6 months and 9th month
Secondary Outcome Measures
NameTimeMethod
As serum IL-6 levels significantly decreased in MMF group, correspondingly no resistance to treatment was noted. However with MTX there was no significant decrease in IL-6 and resistance to treatment was noted in some, especially plaque type lesions. Thus IL-6 can be a possible biomarker in deciding the best possible therapy for treatment resistant OLP.Timepoint: after 6 months period
© Copyright 2025. All Rights Reserved by MedPath